The 2024 CSCO Breast Cancer Guidelines have dedicated a separate section to HER2-low expression, emphasizing the clinical significance of trastuzumab deruxtecan (T-DXd) for treating advanced HER2-low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.